93
Views
29
CrossRef citations to date
0
Altmetric
Article

Circulating level of hepatocyte growth factor as a useful tumor marker in patients with early‐stage gastric carcinoma

, , , , &
Pages 754-760 | Received 05 May 2003, Accepted 29 Feb 2004, Published online: 08 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Fatemeh Moosavi, Elisa Giovannetti, Luciano Saso & Omidreza Firuzi. (2019) HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers. Critical Reviews in Clinical Laboratory Sciences 56:8, pages 533-566.
Read now
Cara L Cooke, Javier Torres & Jay V Solnick. (2013) Biomarkers of -associated gastric cancer. Gut Microbes 4:6, pages 532-540.
Read now

Articles from other publishers (27)

Jieun Jang, Seung Hyun Ma, Kwang-Pil Ko, Bo Yul Choi, Keun-Young Yoo & Sue K. Park. (2020) Hepatocyte Growth Factor in Blood and Gastric Cancer Risk: A Nested Case–Control Study. Cancer Epidemiology, Biomarkers & Prevention 29:2, pages 470-476.
Crossref
Yung-Jue Bang, Do-Youn Oh, Han-Kwang Yang, Sang Gyun Kim & Woo-Ho Kim. 2019. Textbook of Gastrointestinal Oncology. Textbook of Gastrointestinal Oncology 73 95 .
Takahiro Tsuji, Yuichi Sakamori, Hiroaki Ozasa, Yoshitaka Yagi, Hitomi Ajimizu, Yuto Yasuda, Tomoko Funazo, Takashi Nomizo, Hironori Yoshida, Hiroki Nagai, Ken Maeno, Tetsuya Oguri, Toyohiro Hirai & Young Hak Kim. (2017) Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancer. Oncotarget 8:42, pages 71805-71816.
Crossref
Do-Youn Oh & Yung-Jue Bang. 2017. Immunotherapy for Gastrointestinal Cancer. Immunotherapy for Gastrointestinal Cancer 101 113 .
Oscar Arrieta, Graciela Cruz-Rico, Enrique Soto-Perez-de-Celis, Laura-Alejandra Ramírez-Tirado, Enrique Caballe-Perez, Jorge-Negueb Martínez-Hernández, Ivan Martinez-Alvarez, Giovanny Soca-Chafre, Eleazar Omar Macedo-Pérez & Horacio Astudillo-de la Vega. (2016) Reduction in Hepatocyte Growth Factor Serum Levels is Associated with Improved Prognosis in Advanced Lung Adenocarcinoma Patients Treated with Afatinib: a Phase II Trial. Targeted Oncology 11:5, pages 619-629.
Crossref
Rainer Hügel, Axel Muendlein, Lennart Volbeding, Heinz Drexel, Erika Richtig, Ulrike Wehkamp, Clemes Painsi, Bernhard Lange-Asschenfeldt, Axel Hauschild & Friederike Egberts. (2016) Serum levels of hepatocyte growth factor as a potential tumor marker in patients with malignant melanoma. Melanoma Research 26:4, pages 354-360.
Crossref
Li Yu, Ruhong Zhang, Pengfei Li, Danning Zheng, Jia Zhou, Jian Wang, Bo Zhang & Chang Zhu. (2015) Traditional Chinese Medicine: Salvia miltiorrhiza Enhances Survival Rate of Autologous Adipose Tissue Transplantation in Rabbit Model. Aesthetic Plastic Surgery 39:6, pages 985-991.
Crossref
Yilong Zhang, Rajul Jain & Min Zhu. (2015) Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment. Biomedicines 3:1, pages 149-181.
Crossref
M Zhu, R Tang, S Doshi, K S Oliner, S Dubey, Y Jiang, R C Donehower, T Iveson, E Y Loh & Y Zhang. (2015) Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression. British Journal of Cancer 112:3, pages 429-437.
Crossref
HITOMI UMEGUCHI, NAOKO SUEOKA-ARAGANE, NAOMI KOBAYASHI, TOMOMI NAKAMURA, AKEMI SATO, YUJI TAKEDA, SHINICHIRO HAYASHI, EISABURO SUEOKA & SHINYA KIMURA. (2015) Usefulness of plasma HGF level for monitoring acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer. Oncology Reports 33:1, pages 391-396.
Crossref
Jonathan Cools-Lartigue, Laura Baker & Lorenzo E. Ferri. 2015. Gastric Cancer. Gastric Cancer 35 56 .
Timothy Iveson, Ross C Donehower, Irina Davidenko, Sergey Tjulandin, Andrzej Deptala, Mark Harrison, Somanath Nirni, Kuntegowdanahalli Lakshmaiah, Anne Thomas, Yizhou Jiang, Min Zhu, Rui Tang, Abraham Anderson, Sarita Dubey, Kelly S Oliner & Elwyn Loh. (2014) Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. The Lancet Oncology 15:9, pages 1007-1018.
Crossref
Y. Mohri, C. Miki, K. Tanaka, A. Kawamoto, M. Ohi, T. Yokoe & M. Kusunoki. (2012) Clinical Correlations and Prognostic Relevance of Tissue Angiogenic Factors in Patients with Gastric Cancer. Clinical Oncology 24:9, pages 610-616.
Crossref
RUI SUN, QING ZHANG, LING GUO, MING-YUAN CHEN, YING SUN, BRIAN CAO & JIAN SUN. (2012) HGF stimulates proliferation through the HGF/c-Met pathway in nasopharyngeal carcinoma cells. Oncology Letters 3:5, pages 1124-1128.
Crossref
Guro Aune, Astrid Kamilla Stunes, Aina-Mari Lian, Janne Elin Reseland, Solveig Tingulstad, Sverre H. Torp & Unni Syversen. (2012) Circulating interleukin-8 and plasminogen activator inhibitor-1 are increased in women with ovarian carcinoma. Results in Immunology 2, pages 190-195.
Crossref
Guro Aune, Aina-Mari Lian, Solveig Tingulstad, Sverre H. Torp, Siri Forsmo, Janne Elin Reseland, Astrid Kamilla Stunes & Unni Syversen. (2011) Increased circulating hepatocyte growth factor (HGF): A marker of epithelial ovarian cancer and an indicator of poor prognosis. Gynecologic Oncology 121:2, pages 402-406.
Crossref
Kazuo Kasahara, Tokuzo Arao, Kazuko Sakai, Kazuko Matsumoto, Asao Sakai, Hideharu Kimura, Takashi Sone, Atsushi Horiike, Makoto Nishio, Tatsuo Ohira, Norihiko Ikeda, Takeharu Yamanaka, Nagahiro Saijo & Kazuto Nishio. (2010) Impact of Serum Hepatocyte Growth Factor on Treatment Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non–Small Cell Lung Adenocarcinoma. Clinical Cancer Research 16:18, pages 4616-4624.
Crossref
Julian A. Abrams & Timothy C. Wang. 2010. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Sleisenger and Fordtran's Gastrointestinal and Liver Disease 887 906.e8 .
Olivier De Wever, Patrick Pauwels, Bram De Craene, Michèle Sabbah, Shahin Emami, Gérard Redeuilh, Christian Gespach, Marc Bracke & Geert Berx. (2008) Molecular and pathological signatures of epithelial–mesenchymal transitions at the cancer invasion front. Histochemistry and Cell Biology 130:3.
Crossref
Takashi Muramatsu & Hisako Muramatsu. (2008) Glycosaminoglycan-binding cytokines as tumor markers. PROTEOMICS 8:16, pages 3350-3359.
Crossref
Barbara Mroczko, Magdalena Groblewska, Urszula Wereszczyńska-Siemiątkowska, Bogna Okulczyk, Bogusław Kędra, Wiktor Łaszewicz, Andrzej Dąbrowski & Maciej Szmitkowski. (2007) Serum macrophage-colony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis. Clinica Chimica Acta 380:1-2, pages 208-212.
Crossref
C.-Y. Hsia, T.-I. Huo, S.-Y. Chiang, M.-F. Lu, C.-L. Sun, J.-C. Wu, P.-C. Lee, C.-W. Chi, W.-Y. Lui & S.-D. Lee. (2007) Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma. European Journal of Surgical Oncology (EJSO) 33:2, pages 208-212.
Crossref
Chikao Miki, Yasuhiro Inoue, Jun-ichiro Hiro, Eiki Ojima, Toshimitsu Araki, Keiichi Uchida & Masato Kusunoki. (2006) Combined Measurement of Hepatocyte Growth Factor and Carcinoembryonic Antigen as a Prognostic Marker for Patients with Dukes A and B Colorectal Cancer: Results of a Five-Year Study. Diseases of the Colon & Rectum 49:11, pages 1710-1718.
Crossref
Marc G. Achen & Steven A. Stacker. (2006) Tumor lymphangiogenesis and metastatic spread—New players begin to emerge. International Journal of Cancer 119:8, pages 1755-1760.
Crossref
Matthias P.A. Ebert & Christoph R??cken. (2006) Molecular screening of gastric cancer by proteome analysis. European Journal of Gastroenterology & Hepatology 18:8, pages 847-853.
Crossref
Christine Chaponnier, Alexis Desmoulière & Giulio GabbianiOlivier De Wever & Marc Mareel. 2006. Tissue Repair, Contraction and the Myofibroblast. Tissue Repair, Contraction and the Myofibroblast 74 87 .
Keiji Shimizu, Yuji Ueda & Hisakazu Yamagishi. (2005) Titration of serum p53 antibodies in patients with gastric cancer: a single-institute study of 40 patients. Gastric Cancer 8:4, pages 214-219.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.